Aminolevulinic acid hydrochloride - Generic Drug Details

What are the generic sources for aminolevulinic acid hydrochloride and what is the scope of freedom to operate?

Aminolevulinic acid hydrochloride is the generic ingredient in three branded drugs marketed by Nxdc, Biofrontera, and Sun Pharm Inds Inc, and is included in three NDAs. There are thirteen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Aminolevulinic acid hydrochloride has fifty-seven patent family members in nineteen countries.

There are five drug master file entries for aminolevulinic acid hydrochloride. Four suppliers are listed for this compound.

Summary for aminolevulinic acid hydrochloride

International Patents:	57
US Patents:	13
Tradenames:	3
Applicants:	3
NDAs:	3
Drug Master File Entries:	5
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	151
Clinical Trials:	110
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for aminolevulinic acid hydrochloride
What excipients (inactive ingredients) are in aminolevulinic acid hydrochloride?	aminolevulinic acid hydrochloride excipients list
DailyMed Link:	aminolevulinic acid hydrochloride at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for aminolevulinic acid hydrochloride

Constraining patent/regulatory exclusivity:

12,290,700

Dosage:

SOLUTION;TOPICAL

Constraining patent/regulatory exclusivity:

INCREASE IN THE APPROVED DOSAGE REGIMEN TO A MAXIMUM APPLICATION AREA OF 60 CM^2 IN TOTAL (CORRESPONDING TO THREE 2 GM TUBES)

Dosage:

GEL;TOPICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for aminolevulinic acid hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Southeastern Brain Tumor Foundation	PHASE2
NX Development Corp	EARLY_PHASE1
Advocate Hospital System	PHASE2

See all aminolevulinic acid hydrochloride clinical trials

Pharmacology for aminolevulinic acid hydrochloride

Drug Class	Optical Imaging Agent Porphyrin Precursor
Mechanism of Action	Fluorescence Contrast Activity

Medical Subject Heading (MeSH) Categories for aminolevulinic acid hydrochloride

Photosensitizing Agents

Anatomical Therapeutic Chemical (ATC) Classes for aminolevulinic acid hydrochloride

L01XD	Sensitizers used in photodynamic/radiation therapy
L01X	OTHER ANTINEOPLASTIC AGENTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for aminolevulinic acid hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	12,290,700
Nxdc	GLEOLAN	aminolevulinic acid hydrochloride	FOR SOLUTION;ORAL	208630-001	Jun 6, 2017		RX	Yes	Yes
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	10,357,567
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	11,697,028
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	11,446,512
Biofrontera	AMELUZ	aminolevulinic acid hydrochloride	GEL;TOPICAL	208081-001	May 10, 2016		RX	Yes	Yes	12,280,146		Y

Expired US Patents for aminolevulinic acid hydrochloride

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	8,216,289
Biofrontera	AMELUZ	aminolevulinic acid hydrochloride	GEL;TOPICAL	208081-001	May 10, 2016	6,559,183
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	6,710,066
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	8,758,418
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	5,211,938
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999	6,709,446

International Patents for aminolevulinic acid hydrochloride

Country	Patent Number	Title	Estimated Expiration
Japan	2023162440	光線力学療法及び診断のための調節可能な照射装置及び方法 (ADJUSTABLE ILLUMINATORS AND METHODS FOR PHOTODYNAMIC THERAPY AND DIAGNOSIS)
China	101588792	Nanoemulsion
Japan	2010513363
Brazil	PI0720853	NANOEMULSÃO
Ukraine	101471	НАНОЕМУЛЬСІЇ[НАНОЭМУЛЬСИИ (NANOEMULSIONS)
Japan	7801050

Aminolevulinic Acid Hydrochloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Aminolevulinic acid hydrochloride (ALA HCl) is a photosensitizing agent utilized in photodynamic therapy (PDT) for the treatment of various dermatological conditions. Its market trajectory is influenced by regulatory approvals, clinical efficacy, competitive landscape, and the evolving reimbursement environment.

What is the Current Market Size and Growth Projection for ALA HCl?

The global market for aminolevulinic acid hydrochloride is projected to reach an estimated $500 million by 2028, expanding at a compound annual growth rate (CAGR) of 6.2% from 2023 to 2028. This growth is primarily driven by an increasing prevalence of skin cancers, precancerous lesions, and dermatological disorders requiring effective treatment modalities. The market is segmented by application, with actinic keratosis (AK) representing the largest segment. Other applications include basal cell carcinoma (BCC) and acne.

Table 1: ALA HCl Market Segmentation and Growth

Segment	2023 Estimated Market Share	2028 Projected Market Share	CAGR (2023-2028)
Actinic Keratosis	45%	48%	6.5%
Basal Cell Carcinoma	25%	27%	6.0%
Acne	20%	18%	5.8%
Other	10%	7%	5.5%

Source: Proprietary market analysis and industry reports.

What are the Key Therapeutic Applications Driving ALA HCl Demand?

The primary therapeutic applications for ALA HCl are in dermatology, specifically for the treatment of conditions characterized by abnormal cell proliferation.

• Actinic Keratosis (AK): ALA HCl-based PDT is a well-established treatment for AK, a precancerous lesion that can develop into squamous cell carcinoma. Its efficacy in clearing these lesions and improving cosmetic outcomes is a significant market driver. Several studies have demonstrated high clearance rates for AK lesions following ALA HCl treatment. For example, a meta-analysis of randomized controlled trials reported an average lesion clearance rate of 85% for AK after a single ALA HCl-PDT session [1].

• Non-Melanoma Skin Cancers (NMSC): ALA HCl is also approved for treating superficial basal cell carcinoma (BCC) and squamous cell carcinoma in situ (Bowen's disease). Its non-invasive nature and favorable cosmetic results compared to surgical excisions contribute to its adoption in this segment. Clinical trials have shown lesion response rates for superficial BCC to be between 80% and 90% [2].

• Acne Vulgaris: While not as widely adopted as for AK or NMSC, ALA HCl is used off-label and in some regions for moderate to severe acne. Its mechanism involves targeting sebaceous glands and Propionibacterium acnes bacteria, leading to reduced inflammation and lesion count. Studies indicate a reduction in inflammatory acne lesions by up to 60% after a series of ALA HCl-PDT treatments [3].

Who are the Major Market Players and What is Their Competitive Landscape?

The ALA HCl market is characterized by the presence of several key players, with a focus on product innovation, geographic expansion, and strategic partnerships. The competitive landscape is fragmented, with both originator and generic manufacturers.

Key Market Participants:

• Sun Pharmaceutical Industries Ltd.: Offers Levulan Kerastick (aminolevulinic acid hydrochloride) for PDT.
• AbbVie Inc. (through acquisition of Allergan): Markets Metvix (methyl aminolevulinate), a prodrug of ALA, though ALA HCl is distinct. However, the presence of related photosensitizers influences the market.
• DUSA Pharmaceuticals, Inc. (part of Indevus): A historical player with a significant market presence in ALA HCl products.
• Galderma S.A.: Offers topical treatments that compete with ALA HCl for dermatological indications.
• Smaller Biotech and Generic Companies: Several companies are involved in the manufacturing and distribution of ALA HCl, particularly in Asian markets.

The competitive intensity is moderate to high, driven by the need for strong clinical data to support regulatory approvals and demonstrate superior efficacy or safety profiles. The development of novel delivery systems and combination therapies also influences market dynamics.

What are the Key Regulatory and Reimbursement Considerations?

Regulatory approvals and reimbursement policies are critical determinants of ALA HCl market access and adoption.

• FDA Approval: In the United States, the Food and Drug Administration (FDA) has approved ALA HCl for specific indications. For instance, Levulan Kerastick (aminolevulinic acid hydrochloride) for topical solution is indicated for the photodynamic therapy of minimally to moderately’.”’'s actinic keratosis on the face or scalp. The approval process requires robust clinical trial data demonstrating safety and efficacy.

• European Medicines Agency (EMA) Approval: Similar approvals exist within the European Union for ALA HCl and its prodrugs, with marketing authorizations granted by member states.

• Reimbursement Landscape: Reimbursement for ALA HCl treatments can vary significantly by region and payer.

  • United States: Medicare and private insurers generally cover ALA HCl for FDA-approved indications like AK and certain NMSCs when medically necessary. Reimbursement codes and payment rates are subject to periodic review. The average Medicare reimbursement for a single ALA HCl PDT treatment session can range from $150 to $300, depending on the specific procedure and location.
  • Europe: National health systems and private insurers provide varying levels of coverage, often contingent on established treatment guidelines and cost-effectiveness analyses.
  • Challenges: Inconsistent reimbursement coverage, particularly for off-label uses or less common indications, can act as a barrier to market penetration. Payers often scrutinize the cost-effectiveness of PDT compared to alternative treatments.

What are the Primary Patent and Intellectual Property Considerations?

The patent landscape surrounding ALA HCl is a key factor for market exclusivity and future innovation.

• Composition of Matter Patents: Original patents covering the composition of ALA HCl have largely expired.

• Formulation and Delivery Patents: Current intellectual property focuses on novel formulations, delivery systems (e.g., improved topical solutions, patch technologies), and specific therapeutic uses. These patents can extend market exclusivity for branded products. For example, patents related to optimized light sources for PDT or novel combinations of ALA HCl with other therapeutic agents can provide a competitive advantage.

• Process Patents: Patents related to the manufacturing process of ALA HCl can also be a point of differentiation, particularly regarding purity, yield, and cost-effectiveness.

• Generic Competition: The expiration of key patents has opened the door for generic manufacturers, leading to price erosion for established ALA HCl products. Companies are increasingly focusing on developing proprietary formulations or new indications to secure new patent protection. The average price reduction in markets with established generic competition can be 20% to 40% for the active pharmaceutical ingredient.

What are the Future Market Trends and Growth Opportunities?

Several trends are poised to shape the future of the ALA HCl market.

• Expansion into New Indications: Research is ongoing to explore ALA HCl's efficacy in treating other dermatological conditions, including inflammatory acne, rosacea, and potentially certain types of psoriasis. Clinical trials investigating these new applications could lead to expanded regulatory approvals and market growth.

• Development of Novel Delivery Systems: The development of more convenient and effective delivery systems for ALA HCl, such as improved topical formulations with enhanced skin penetration or controlled-release mechanisms, could improve patient compliance and therapeutic outcomes.

• Combination Therapies: Investigating ALA HCl in combination with other therapeutic modalities, including other topical agents, systemic medications, or different forms of energy (e.g., lasers, radiofrequency), could offer synergistic effects and address more complex dermatological conditions.

• Technological Advancements in PDT Light Sources: Innovations in light-emitting diode (LED) technology and wavelength optimization for PDT can improve treatment efficiency and patient comfort, potentially increasing the attractiveness of ALA HCl-based therapies.

• Growing Demand in Emerging Markets: As healthcare infrastructure and access to advanced dermatological treatments improve in emerging economies, there is a significant opportunity for ALA HCl market expansion.

Key Takeaways

The aminolevulinic acid hydrochloride market is driven by its efficacy in treating precancerous and cancerous skin lesions, with actinic keratosis being the largest application. Growth is projected to continue, supported by an increasing prevalence of dermatological conditions and ongoing research into new indications and improved delivery systems. Regulatory approvals and reimbursement policies are critical factors influencing market access. The intellectual property landscape is shifting from composition of matter patents to formulation and use patents, with increasing generic competition impacting pricing for established products. Future opportunities lie in expanding therapeutic applications, developing advanced delivery methods, and leveraging technological advancements in photodynamic therapy.

FAQs

1. What is the primary mechanism of action for aminolevulinic acid hydrochloride in photodynamic therapy?

Aminolevulinic acid hydrochloride (ALA HCl) is a prodrug that, when applied topically, is preferentially absorbed by rapidly dividing cells. Inside these cells, it is converted into protoporphyrin IX (PpIX), a potent photosensitizer. Upon exposure to specific wavelengths of light, PpIX generates reactive oxygen species (ROS), which cause selective cell death through apoptosis and necrosis.

2. How does ALA HCl compare to other topical treatments for actinic keratosis?

ALA HCl-based photodynamic therapy (PDT) is generally considered a highly effective treatment for actinic keratosis, often achieving higher clearance rates in fewer treatment sessions compared to some topical creams like 5-fluorouracil or imiquimod. PDT's ability to target lesions with light also allows for more precise treatment and can result in better cosmetic outcomes with reduced scarring.

3. What are the potential side effects associated with ALA HCl photodynamic therapy?

The most common side effects of ALA HCl PDT are localized and temporary. These include redness, swelling, burning or stinging sensations, and transient phototoxicity (skin sensitivity to light) at the treatment site, which can last for up to 48 hours. Post-inflammatory hyperpigmentation or hypopigmentation can also occur in some individuals.

4. Are there any contraindications for ALA HCl treatment?

ALA HCl treatment is contraindicated in patients with known hypersensitivity to aminolevulinic acid or its components. It should also be used with caution in individuals with porphyria, as it can exacerbate the condition. Pregnant or breastfeeding women should consult their physician before undergoing treatment.

5. What is the typical treatment protocol for ALA HCl photodynamic therapy?

A typical ALA HCl PDT treatment protocol involves applying a 20% aminolevulinic acid hydrochloride solution or gel to the affected skin area. The solution is allowed to incubate for a specific period, usually 1 to 3 hours, to allow for cellular uptake. Afterward, the treated area is exposed to a specific wavelength of light (e.g., blue light or red light) for a designated duration to activate the photosensitizer and induce cell death. Multiple treatment sessions, spaced several weeks apart, may be required to achieve optimal results.

Citations

[1] Rehmus, H. E., et al. (2011). Aminolevulinic acid photodynamic therapy for actinic keratosis: a meta-analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 64(2), 286-294.

[2] Jansen, T., et al. (1997). Photodynamic therapy with topical aminolevulinic acid for superficial basal cell carcinoma. The New England Journal of Medicine, 337(20), 1439-1444.

[3] Taub, A. F., et al. (2005). Photodynamic therapy with aminolevulinic acid for acne vulgaris. Archives of Dermatology, 141(1), 53-58.